TGFB1 and neoplasm: These findings suggest that the absence of IL-6 signaling in the TME might impair the antitumor efficacy of the TGFβ vaccine by increasing the infiltration of myeloid cells and TAMs into the tumor, reducing the frequency of proinflammatory TAMs and increasing the suppressive phenotype of anti-inflammatory TAMs.